November 21, 2014
The addition of trastuzumab to adjuvant chemotherapy conferred “substantial and durable improvement in survival” among women with early-stage, HER-2–positive breast cancer, according to a joint analysis of long-term results from randomized two trials.
“This study reflects that excellent science in collaboration between NCI-sponsored cancer cooperative groups and our patients can clearly help improve standards of care,” Edith A. Perez, MD, director of the breast cancer program at Mayo Clinic in Jacksonville, Fla., and a HemOnc Today Editorial Board member, told HemOnc Today. “Some specifics included a very low rate of local recurrence and serious cardiac side effects, even though all patients received anthracyclines prior to paclitaxel–trastuzumab. This regimen is a well-established standard of care regimen for eligible patients.”